Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon β-1b

Neurology

Volumn 47, Issue 6, 1996, Pages 1463-1468

  Pliskin, N H ^a,b   Hamer, D P ^a   Goldstein, D S ^a   Towle, V L ^a   Reder, A T ^a   Noronha, A ^a   Arnason, B G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCORING SYSTEM; TASK PERFORMANCE; VISION TEST;

EID: 0029753268     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1463     Document Type: Article

References (40)

1. The IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DK, the University of British Columbia MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 662-667.
3. Connelly JF. Interferon beta for multiple sclerosis [review]. Ann Pharmacotherapy 1994;28:610-616.
4. Goodkin DE, Cookfair D, Wende K, et al. and the Multiple Sclerosis Collaborative Research Group. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992;42: 859-863.
5. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-691.
6. Rao SM. Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol 1986;8:503-542.
7. Ryan JJ and Paolo AM. A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol 1992; 6:53-62.
8. Nelson HE. National adult reading test (NART): test manual. Windsor, U.K.: NFER Nelson, 1982.
9. Wechsler D. A standardized memory scale for clinical use. J Clin Psychol 1945;19:87-95.
10. Russell EW. Renorming Russell's version of the Wechsler Memory Scale. J Clin Exp Neuropsychol 1988;10:235-249.
11. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Tucson: Neuropsychology Press, 1985.
12. Golden CJ. Stroop color and word test, catalogue number 30150M. A manual for clinical and experimental uses. Chicago: Stoelting Company, 1978.
13. Tiffin J. Purdue pegboard: examiner manual. Chicago: Science Research Associates, 1968.
14. Beck AT. Beck depression inventory: manual. San Antonio: Psychological Corporation, 1987.
15. Heaton RF, Grant I, Mathews CG. Comprehensive norms for an expanded Halstead-Reitan battery. Demographic corrections, research findings, and clinical applications. Odessa: Psychological Corporation, 1991.
16. Zonderman AB, Giambra LM, Arenberg D, Resnick SM, Costa PT Jr. Changes in immediate visual memory predict cognitive impairment. Arch Clin Neuropsychol 1995;10:111-123.
17. Schultz EE Jr, Keesler TY, Friedenberg L, Sciara AD. Limitations in equivalence of alternate subtests for Russell's revision of the Wechsler memory scale: causes and solutions. J Clin Neuropsychol 1984;6:220-223.
18. Keesler TY, Schultz EE Jr, Sciara AD, Friedenberg L. Equivalence of alternate subtests for the Russell revision of the Wechsler memory scale. J Clin Neuropsychol 1984;6:215-219.
19. Reitan RM. The relation of the trail making test to organic brain damage. J Gen Psychol 1955f;53:97-107.
20. Reitan RM. The validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
21. Jarvis PE, Barth JT. The Halstead-Reitan neuropsychological battery. A guide to interpretation and clinical applications. Odessa: Psychological Assessment Resources, 1994.
22. The IFN Beta Multiple Sclerosis Study Group. Beta interferon 1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1996 (in press).
23. Giesser BS, Schroeder MM, LaRocca NG, et al. Endogenous event-related potentials as indices of dementia in multiple sclerosis patients. Electroencephalogr Clin Neurophysiol 1992;82:320-329.
24. Gil R, Zai L, Neau JP, et al. Event-related auditory evoked potentials and multiple sclerosis. Electroencephalogr Clin Neurophysiol 1993;88:182-187.
25. Newton MR, Barrett G, Callanan MM, Towell AD. Cognitive event-related potentials in multiple sclerosis. Brain 1989;112: 1637-1660.
26. Dooley JS, Davis GL, Peters M, et al. Pilot study of recombinant human A-interferon for chronic type B hepatitis. Gastroenterology 1986;90:150-157.
27. Priestman TJ. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. Lancet 1980;2:113-118.
28. Scott GM, Secher DS, Flowers D, et al. Toxicity of interferon. BMJ 1981;282:1345-1348.
29. Sherwin SA, Knost JA, Fein S, et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982;248:2461-2466.
30. Farkkila M, Iivanainen M, Roine R, et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984;69:42-46.
31. Iivanainen M, Laaksonen R, Niemi M-L, et al. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985;72:475-480.
32. Mattson K, Niiranen A, Laaksonen R, et al. Psychometric monitoring of interferon neurotoxicity. Lancet 1984;1:275-276.
33. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676.
34. Niiranen A, Laaksonen R, Iivanainen M, et al. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr Scand 1988;78:622-626.
35. Arnason BGW and Reder AT. Interferons and multiple sclerosis. Clin Neuropharm 1994;17:495-547.
36. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413.
37. Pozzilli C, Passafiume D, Bernardi S, et al. Spect, MRI and cognitive dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatr 1991;54:110-115.
38. Rao SM, Leo GJ, Haughton VM, St. Aubin-Faubert P, Bernardin BS. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161-166.
39. Ron MA, Callanan MM, Warrington EK. Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. Psychol Med 1991;21:59-68.
40. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 1995;37:611-619.